You are here: Industry Insights > Amgen

News List

Amgen and Boston Children's Hospital to identify new targets for pain syndromes pharmaceufical-technology
October 19, 2017
The pain syndromes will also include paroxysmal extreme pain disorder, a condition characterised by skin flushing and severe pain attacks in various parts of the body, as well as hereditary sensory and autonomic neuropathy.
Amgen’s China biosim deal, Sovaldi’s Chinese nod, Shanghai Pharma’s Alvogen talks fiercepharma
September 30, 2017
Gilead's Chinese nod for Sovaldi, a potential sale of Alvogen's U.S. business to Shanghai Pharma, and more.
AbbVie Resolves HUMIRA® Patent Disputes with Amgen americanpharmaceuticacreview
September 30, 2017
AbbVie has announced a global resolution of all intellectual property-related litigation with Amgen over Amgen's proposed biosimilar adalimumab product.
Thanks to Amgen biosim settlement, AbbVie’s $20B Humira forecast looks real fiercepharma
September 29, 2017
AbbVie's assertion that Humira will sail clear for several years gained strength on Thursday as the drugmaker inked a patent settlement with Amgen, holding off that company's biosimilar until 2023.
Amgen and Simcere partner to develop and commercialise biosimilars in China pharmaceufical-technology
September 29, 2017
US-based biotechnology company Amgen has entered an exclusive agreement with Chinese firm Simcere Pharmaceutical Group to co-develop and commercialise four biosimilars in China.
Amgen, Simcere to Co-Develop and Commercialize Biosimilars in China americanpharmaceuticacreview
September 28, 2017
Amgen and Simcere Pharmaceutical Group announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China.
Amgen and Simcere announce strategic collaboration to co-develop and commercialize biosimilars in Ch worldpharmanews
September 28, 2017
Amgen (NASDAQ: AMGN) and Simcere Pharmaceutical Group have announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China.
Amgen Foundation pledges up to $5 million to Hurricane Maria relief efforts worldpharmanews
September 26, 2017
Amgen (NASDAQ:AMGN) announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico.
Amgen and Allergan’s anti-cancer biosimilar Mvasi receives FDA approval pharmaceufical-technology
September 19, 2017
The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) for the treatment of five types of cancer.
Amgen and Allergan win FDA nod for biosimilar of Avastin, Roche's $3B seller fiercepharma
September 15, 2017
The FDA has ushered in a new era in lower cost cancer medicines with its approval of Amgen’s and Allergan's Mvasi, a biosimilar of Roche’s blockbuster drug Avastin.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page